
Brukinsa More Cost-Effective and Keeps Cancer from Progressing Longer Than Imbruvica
Brukinsa (zanubrutinib) and Imbruvica (ibrutinib) are Bruton tyrosine kinase (BTK) inhibitors FDA-approved to treat chronic lymphocytic leukemia (CLL) in adults, among other blood cancers. In 2013, AbbVie and Janssen Biotech's Imbruvica was the first …